61 articles tagged with #drug-discovery. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Researchers introduce GlassMol, a new interpretable AI model for molecular property prediction that addresses the black-box problem in drug discovery. The model uses Concept Bottleneck Models with automated concept curation and LLM-guided selection, achieving performance that matches or exceeds traditional black-box models across thirteen benchmarks.
Researchers propose a new iterative distillation framework for fine-tuning diffusion models in biomolecular design that optimizes for specific reward functions. The method addresses stability and efficiency issues in existing reinforcement learning approaches by using off-policy data collection and KL divergence minimization for improved training stability.
Researchers have developed VCWorld, a new AI-powered biological simulation system that combines large language models with structured biological knowledge to predict cellular responses to drug perturbations. The system operates as a 'white-box' model, providing interpretable predictions and mechanistic insights while achieving state-of-the-art performance in drug perturbation benchmarks.
Researchers have developed GenAI-Net, a generative AI framework that automates the design of chemical reaction networks (CRNs) for synthetic biology applications. The system can automatically generate biomolecular circuits for various functions including logic gates, oscillators, and classifiers, potentially accelerating the development of biomanufacturing and therapeutic technologies.
Google DeepMind has launched AlphaGenome, an AI tool that analyzes the 98% of human DNA that doesn't code for proteins but regulates gene expression. The deep-learning platform can predict 11 types of biological signals and is already being used by thousands of scientists worldwide for cancer research, drug discovery, and synthetic DNA design.
AlphaFold, Google DeepMind's AI protein structure prediction system, has successfully revealed the structure of a key protein associated with heart disease. This breakthrough demonstrates AI's growing capability in medical research and drug discovery applications.
NVIDIA CEO Jensen Huang participated in a fireside chat at the J.P. Morgan Healthcare Conference, discussing AI applications across healthcare sectors including genomic research, drug discovery, clinical trials, and patient care. The discussion highlighted how AI is making significant inroads throughout the entire healthcare industry.
Researchers have developed FlexMS, a flexible benchmark framework for evaluating deep learning models that predict mass spectra for molecular identification in drug discovery and material science. The framework addresses current challenges in assessing different prediction approaches by providing standardized evaluation methods and insights into performance factors across various model architectures.
Drug-resistant infections are increasing due to antibiotic overuse and misuse, while development of new antibacterial treatments has slowed. Synthetic biology and AI are being explored as potential solutions to address the growing global antimicrobial resistance threat.
Professor James Collins discusses how collaboration has been central to his research combining computational predictions with experimental platforms to accelerate therapeutic drug discovery and design using AI technologies.
The article title suggests SAIR is leveraging AI technology to accelerate pharmaceutical research and development through structural intelligence capabilities. However, without the article body content, specific details about the technology, partnerships, or market impact cannot be analyzed.
